-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Wonderful content
Wonderful contentA few days ago, Hengrui Medicine issued an announcement stating that the company has obtained approval for its imitation of Propofol medium/long-chain fat emulsion injections for production of 4 categories, and it is deemed to have been reviewed
.
Up to now, the company has invested approximately 21.
Basic situation of drugs
Propofol medium/long-chain fat emulsion injection is a fast-acting short-acting general intravenous anesthetic.
It was developed by Fresenius Kabi and has been approved for marketing in Germany, Austria and other countries
.
In February 2007, Fresenius Kabi was approved for listing in China
Source: One-click search on Mi Nei.
com
According to data from Menet.
com, in 2020, China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal propofol medium/long-chain fat emulsion injection sales exceeded 1.
5 billion yuan.
Among them, Fresenius Kabi has the largest market share, exceeding 50%; Sichuan Guorui Pharmaceutical and Guangdong Jiabo Pharmaceutical rank second and third respectively
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
Up to now, there are 8 propofol medium/long-chain fat emulsion injection manufacturers, of which 6 domestic companies have been evaluated.
Sichuan Guorui Pharmaceutical and Guangdong Jiabo Pharmaceutical have been approved as supplementary applications, and Sichuan Kelun Pharmaceutical Industry, Jiangsu Yingke Biopharmaceuticals, Yangtze River Pharmaceuticals, and Jiangsu Hengrui Pharmaceuticals have been approved in 4 categories of imitations, which are deemed to have been reviewed
.
In addition, 7 companies including Yichang Renfu Pharmaceutical Co.
Source: Listed company announcement, Mi Nei.